Medicare Enrolled
Dr. Bruce Cleeremans, MD
Neurology · Irvine, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Cleeremans from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cleeremans?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Cleeremans
Dr. Bruce Cleeremans is a neurology specialist in Irvine, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Cleeremans performed 536 Medicare services across 417 unique beneficiaries.
Between the years covered by Open Payments, Dr. Cleeremans received a total of $24,012 from 84 pharmaceutical and/or device companies across 1155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Cleeremans is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 46% volume in CA
$24,012 industry payments
Medicare Practice Summary
Medicare Utilization ↗536
Medicare services
Top 46% in CA for neurology
417
Unique beneficiaries
$108
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~30 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
272 | $99 | $240 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
143 | $131 | $360 |
| Electromyography of arm or leg muscles A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them. |
88 | $88 | $250 |
| Nerve conduction studies, 5-6 tests A series of 5 to 6 tests that measure how well nerves send electrical signals. The procedure evaluates nerve function and helps identify damage or dysfunction. |
19 | $117 | $180 |
| Nerve conduction studies, 7-8 tests A series of 7 to 8 nerve conduction tests to evaluate how well nerves are sending signals to muscles. |
14 | $156 | $240 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$24,012
Total received (2018-2024)
Avg $3,430/year across 7 years
Top 14% in CA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
84
Companies
1,155
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,972 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$40 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,361
2023
$3,967
2022
$3,743
2021
$3,571
2020
$2,564
2019
$2,161
2018
$2,645
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$1,412
ABBVIE INC.
$446
Novartis Pharmaceuticals Corporation
$297
MDD US Operations, LLC
$291
Lilly USA, LLC
$276
Kyowa Kirin, Inc.
$249
Alexion Pharmaceuticals, Inc.
$240
Neurocrine Biosciences, Inc.
$233
ANI Pharmaceuticals, Inc.
$219
EMD Serono, Inc.
$201
PFIZER INC.
$176
Nevro Corp.
$136
Biogen, Inc.
$134
Eisai Inc.
$129
E.R. Squibb & Sons, L.L.C.
$128
ARGENX US, INC.
$109
BANNER LIFE SCIENCES, LLC
$83
TG Therapeutics, Inc.
$78
MITSUBISHI TANABE PHARMA AMERICA, INC.
$77
HARMONY BIOSCIENCES LLC
$72
Teva Pharmaceuticals USA, Inc.
$72
Azurity Pharmaceuticals, Inc.
$64
Celgene Corporation
$47
Amneal Pharmaceuticals LLC
$44
Janssen Scientific Affairs, LLC
$42
Harmony Biosciences Llc
$33
Sumitomo Pharma America, Inc.
$29
Averitas Pharma Inc.
$23
Alnylam Pharmaceuticals Inc.
$20
Top 3 companies account for 40.2% of 2024 payments
All-time payments by company (2018-2024) ›
UCB, Inc.
$3,378
Novartis Pharmaceuticals Corporation
$2,131
Biogen, Inc.
$1,636
Sunovion Pharmaceuticals Inc.
$1,083
EMD Serono, Inc.
$948
Eisai Inc.
$848
Alexion Pharmaceuticals, Inc.
$798
ABBVIE INC.
$640
Lilly USA, LLC
$609
Kyowa Kirin, Inc.
$609
Teva Pharmaceuticals USA, Inc.
$602
Amgen Inc.
$580
PFIZER INC.
$555
Neurocrine Biosciences, Inc.
$519
AbbVie Inc.
$493
Avanir Pharmaceuticals, Inc.
$419
Genentech USA, Inc.
$398
MDD US Operations, LLC
$374
CSL Behring
$348
EISAI INC.
$325
GENZYME CORPORATION
$319
Celgene Corporation
$281
SK Life Science, Inc.
$250
Amneal Pharmaceuticals LLC
$249
Almatica Pharma LLC
$230
Janssen Pharmaceuticals, Inc
$227
ACADIA Pharmaceuticals Inc
$222
ANI Pharmaceuticals, Inc.
$219
ARGENX US, INC.
$196
E.R. Squibb & Sons, L.L.C.
$185
Biohaven Pharmaceutical Holding Company Ltd.
$178
Alnylam Pharmaceuticals Inc.
$170
Allergan Inc.
$164
Supernus Pharmaceuticals, Inc.
$161
Neurelis, Inc.
$158
Upsher-Smith Laboratories LLC
$155
Sumitomo Pharma America, Inc.
$152
BANNER LIFE SCIENCES, LLC
$148
MITSUBISHI TANABE PHARMA AMERICA, INC.
$137
Nevro Corp.
$136
Horizon Therapeutics plc
$136
Allergan, Inc.
$135
Mallinckrodt Hospital Products Inc.
$133
UPSHER-SMITH LABORATORIES LLC
$131
Amylyx Pharmaceuticals, Inc.
$125
Biohaven Pharmaceuticals, Inc.
$124
Banner Life Sciences, LLC
$114
INSIGHTEC,INC
$113
Adamas Pharmaceuticals, Inc.
$111
Harmony Biosciences LLC
$104
Merck Sharp & Dohme LLC
$99
Lundbeck LLC
$92
Akcea Therapeutics, Inc.
$91
Azurity Pharmaceuticals, Inc.
$80
TG Therapeutics, Inc.
$78
Acorda Therapeutics, Inc
$78
HARMONY BIOSCIENCES LLC
$72
ARBOR PHARMACEUTICALS, INC.
$65
Catalyst Pharmaceuticals, Inc.
$63
Bausch Health US, LLC
$56
Octapharma USA, Inc.
$55
Cala Health, Inc.
$47
Mallinckrodt Enterprises LLC
$45
IDORSIA PHARMACEUTICALS US INC
$42
Arbor Pharmaceuticals, Inc.
$42
Janssen Scientific Affairs, LLC
$42
Abbott Laboratories
$40
TG THERAPEUTICS, INC.
$39
Takeda Pharmaceuticals U.S.A., Inc.
$38
Assertio Therapeutics, Inc.
$33
Harmony Biosciences Llc
$33
Promius Pharma LLC
$32
Impax Laboratories, Inc.
$31
AstraZeneca Pharmaceuticals LP
$30
CATALYST PHARMACEUTICALS, INC.
$29
Vertical Pharmaceuticals, LLC
$28
Boston Scientific Corporation
$27
SANOFI-AVENTIS U.S. LLC
$26
Averitas Pharma Inc.
$23
ASSERTIO THERAPEUTICS, INC.
$22
Merck Sharp & Dohme Corporation
$20
Scilex Pharmaceuticals Inc.
$19
Corium, LLC
$18
BOSTON SCIENTIFIC CORPORATION
$17
Top 3 companies account for 29.8% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AFINITOR · AIMOVIG · AJOVY · AMPYRA · AMVUTTRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Adlarity · Aduhelm · Aimovig · Austedo XR · BAFIERTAM · BELSOMRA · BOTOX · BRILINTA · BRIUMVI · Briviact · CALA TRIO · CAMBIA · COMIRNATY · COPAXONE · CREXONT · Cambia · Cimzia · DIVIGEL · Dayvigo · EMGALITY · Exablate · FIRDAPSE · FYCOMPA · Fycompa · GILENYA · GOCOVRI · GRALISE · Gocovri · Gralise · HORIZANT · Hizentra · Horizant · INBRIJA · INFINITY · INGREZZA · KESIMPTA · KISUNLA · KYNMOBI · LEMTRADA · LEQEMBI · LINZESS · LOREEV XR · LYRICA · Leqembi · MAVENCLAD · MAYZENT · MIGRANAL · Mavenclad · NAMZARIC · NAPRELAN · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Nayzilam · Neupro · Nourianz · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONGENTYS · ONPATTRO · ONZETRA Xsail · OXTELLAR XR · Ongentys · PANZYGA · PAXLOVID · PURIFIED CORTROPHIN GEL · Ponvory · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · QUTENZA · QUVIVIQ · RADICAVA · RELYVRIO · REXULTI · REYVOW · RYTARY · Rebif · Rystiggo · SOLIRIS · Senza · Soliris · TECFIDERA · TEGSEDI · TOSYMRA · TOSYMRA SUMATRIPTAN NASAL SPRAY · TROKENDI XR · TYSABRI · Trintellix · UBRELVY · ULTOMIRIS · UPLIZNA · VALTOCO · VERCISE · VRAYLAR · VUMERITY · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · WAKIX · ZEMBRACE SYMTOUCH · ZEPOSIA · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH · Zembrace · Zilbrysq
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Neurologists within 10 mi
208
Per 100K population
6.6
County median income
$113,702
Nearest hospital
HOAG ORTHOPEDIC INSTITUTE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Cleeremans is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 14% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Cleeremans experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Cleeremans performed 272 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Cleeremans receive payments from pharmaceutical companies?
Yes. Dr. Cleeremans received a total of $24,012 from 84 companies across 1,155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Cleeremans's costs compare to other neurologists in Irvine?
Dr. Cleeremans's average Medicare payment per service is $108. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Cleeremans) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Irvine
Browse neurologists in Irvine ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in CA
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in CA
Which CA neurologists receive the most from drug and device companies.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology